Alerts
COVID-19 update
See our updated visitor policy, which now allows 1 visitor per patient during exams only. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

Phase III Study of Sacituzumab Govitecan IMMU-132 Versus Treatment of Physician's Choice TPC in subjects with Hormonal Receptor-Positive HR+ Human Epidermal Growth Factor Receptor 2 HER2 Negative Metastatic Breast Cancer MBC who have failed at least two prior chemotherapy regimens

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03901339

Study #:
STUDY00144122

Start Date:
Jan 01, 0001

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03901339

View Complete Trial Details & Eligibility at ClinicalTrials.gov